!!Simon Arnett Jones - Curriculum Vitae
\\
__EDUCATION__
\\
*1994 PhD Biochemistry, University of Bristol \\
*1990 BSc Applied Biological Sciences, Bristol Polytechnic
\\
__ACTIVE GRANTS__ (total income >£16M)
\\
*2015 - 2021 Versus Arthritis Programme Grant. £907,778. How do cytokines signalling through the transcription factors STAT1 and STAT3 determine the course of synovial inflammation? SA Jones (PI), NM Williams, GW Jones, EH Choy, AS Williams, VB O’Donnell\\
*2020 - 2022 Mestag Therapeutics. Novel targeting of cytokine receptors. £347,000. SA Jones\\
*2018 - 2022 GSK. £357,572. IL-27 gene therapy: SA Jones (PI), GW Jones\\
*2019 - 2023 Systems Immunity/Monash University Joint PhD Scheme. £90,000. Cytokine control of disease heterogeneity in synovitis. SA Jones (PI), T Tiganis, SM Turner, NM Williams\\
\\
__RECOGNITION__ 
\\
*Grant panels  \\
*Royal Irish Academy \\
*Early Entry Grant Panel (2008)\\
*Versus Arthritis (Arthritis Research UK)\\
*Research Sub-Committee (2011-16; Vice Chair 2015)\\
*Programme Grant Outline Panel (2015, 2016)\\
*USER Group (Lay panel; 2015, 2016)\\
*Joint Cancer Research UK Partnership Group (2018)\\
*Disease Sub-Committee– (Vice Chair 2017-20)\\
*Health & Care Research Wales \\
*Grants Committee (2012)\\
*Research for Patient & Public Benefit (Deputy Chair; 2013-18)\\
*Health Fellowships Committee (2014)\\
*Health Research Board Ireland \\
*Joint Medical Research Charities Panel (2016, 2018)\\
*Investigator Led Projects (Chair 2019)\\
*Trials Methodology Research Network Review Panel (Chair 2021)\\
*Medical Research Council UKRI \\
*Infection & Immunity Board (2020-24)\\
*COVID-19 Agile Panel (2020-21)\\
*Welsh Government\\
*Sêr Cymru II– College of Experts Independent Evaluation Panel (2015-18)
\\
__Editorial Boards__ 
\\
*Journal Biological Chemistry (2015-20; 2022-27)\\
*Frontiers in Immunology (Review Editor)\\
*Function
\\
__Advisory Panels__ 
\\
*Pharmaceutical companies \\
**Roche/Chugai (tocilizumab); Sanofi-Regeneron (sarilumab); Janssen, EUSA Pharma (siltuximab); Ferring (olamkicept); NovImmune SA (NI-1201; NI-101).\\
*Charities\\
**Versus Arthritis, Senior Stakeholder Group\\
*Government\\
**Welsh Higher Education Brussels Board
\\
__Society Membership__
\\
*International Cytokine & Interferon Society\\
*Organiser of Cytokines2021 (Chair)\\
*Development Committee - exploring industry links
\\
__Meetings Committee__
\\
*Learned Society of Wales\\
*The Royal Soc Biol\\
*Brit Soc Immunology\\
*Am Soc Mol & Cell Biol\\ \\